Bio-energy muscle relaxants
US7148380B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 19, 2001 |
| Grant date | Dec 12, 2006 |
| Priority date | — |
| Expiry date | Jul 2, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/15
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human muscle tissues involve striated and smooth muscles. Each muscle tissue possesses its own special function. Differences of physiology functions among the muscle tissues are mainly determined by their various initiation and signal transmission systems, defined as the pre-muscle molecular motor mechanism, or initiating and regulating mechanism. The current medications, drugs, and therapies for diseases and symptoms related abnormal increased muscle tone or excessive muscle contraction are aimed just at the pre-muscle molecular motor mechanisms, whereas without directly intending to effect on the muscle molecular motor mechanism i.e. the contractile apparatus mechanism at all, which, however, is in common for all kinds of muscle tissues. The muscle molecular motor mechanism mainly involves recycling of actin-myosin filament cross-bridge formation and sliding movement. In the process, bio-energy provided by ATP hydrolysis is necessarily required. Therefore, abnormal increased muscle tone or excessive contraction of muscle tissues under diseased conditions may be modified by inhibition of the muscle molecular motor with the actin-myosin ATPase inhibitor, which blocks hydrolysis of …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.